Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

@article{Heinemann2009ClinicalRO,
  title={Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.},
  author={Volker Heinemann and Sebastian Stintzing and Thomas W. Kirchner and Stefan Hubert Boeck and Andreas Jung},
  journal={Cancer treatment reviews},
  year={2009},
  volume={35 3},
  pages={262-71}
}
The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and tumor progression of colorectal cancer (CRC). As a result, the EGFR has evolved as a relevant target in the treatment of metastatic CRC. KRAS serves as a mediator between extracellular ligand binding and intracellular transduction of signals from the EGFR to the nucleus. The presence of activating KRAS mutations has been identified as a potent predictor of resistance to EGFR-directed antibodies such as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and PCR-RFLP.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie • 2013
View 8 Excerpts
Highly Influenced

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…